Scribe Therapeutics (NASDAQ:SCTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Scribe Therapeutics (NASDAQ:SCTX) to a hold rating in a report published on Saturday.

Scribe Therapeutics Price Performance

Shares of SCTX stock opened at $20.83 on Friday. Scribe Therapeutics has a 52-week low of $17.31 and a 52-week high of $25.49.

Insider Buying and Selling

In related news, Director Behzad Aghazadeh acquired 2,383,333 shares of the firm’s stock in a transaction that occurred on Friday, July 24th. The stock was acquired at an average cost of $15.15 per share, with a total value of $36,107,494.95. Following the completion of the purchase, the director directly owned 3,080,983 shares in the company, valued at approximately $46,676,892.45. This trade represents a 341.62% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Carl L. Gordon acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were bought at an average cost of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the purchase, the director owned 1,348,825 shares of the company’s stock, valued at $20,232,375. This trade represents a 286.68% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 3,727,237 shares of company stock valued at $56,291,746 over the last 90 days.